Association of homologous recombination deficiency (HRD) with clinical outcomes in a phase III study of olaparib or cediranib and olaparib compared to platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer (PSOC): Biomarker analyses from NRG-GY004 Meeting Abstract
| Authors: | Swisher, E.; Miller, A.; Kohn, E.; Brady, M.; Radke, M.; Pennil, C.; Khasnavis, N.; Buscema, J.; Tew, W.; Muller, C.; Hill, E.; Moore, R.; Michelin, D.; Waggoner, S.; Geller, M.; Fujiwara, K.; D'Andre, S.; Liu, J.; Birrer, M. J. |
| Abstract Title: | Association of homologous recombination deficiency (HRD) with clinical outcomes in a phase III study of olaparib or cediranib and olaparib compared to platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer (PSOC): Biomarker analyses from NRG-GY004 |
| Meeting Title: | ESMO Congress 2021 |
| Journal Title: | Annals of Oncology |
| Volume: | 32 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2021 Sep 16-21 |
| Meeting Location: | Virtual |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2021-09-01 |
| Start Page: | S1309 |
| Language: | English |
| ACCESSION: | WOS:000700527703510 |
| DOI: | 10.1016/j.annonc.2021.08.2111 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: LBA34 -- Source: Wos |
